Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

UNLABELLED Kidney cancers often delete chromosome 3p, spanning the VHL tumor suppressor gene, and chromosome 14q, which presumably harbors ≥ 1 tumor suppressor genes. pVHL inhibits the hypoxia-inducible transcription factor (HIF), and HIF2α is a kidney cancer oncoprotein. In this article, we identify focal, homozygous deletions of the HIF1α locus on 14q in clear cell renal carcinoma cell lines. Wild-type HIF1α suppresses renal carcinoma growth, but the products of these altered loci do not. Conversely, downregulation of HIF1α in HIF1α-proficient lines promotes tumor growth. HIF1α activity is diminished in 14q-deleted kidney cancers, and all somatic HIF1α mutations identified in kidney cancers tested to date are loss of function. Therefore, HIF1α has the credentials of a kidney cancer suppressor gene. SIGNIFICANCE Deletion of 14q is a frequent event in clear cell renal carcinoma and portends a poor prognosis. In this study, we provide genetic and functional evidence that HIF1α is a target of 14q loss in kidney cancer.

[1]  Daniel J. Peet,et al.  Cell-specific Regulation of Hypoxia-inducible Factor (HIF)-1α and HIF-2α Stabilization and Transactivation in a Graded Oxygen Environment* , 2006, Journal of Biological Chemistry.

[2]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[3]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[4]  H. Kumon,et al.  Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma. , 2004, Urology.

[5]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[6]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[7]  K. Harvey,et al.  The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network , 2007, Nature Reviews Cancer.

[8]  P. Carmeliet,et al.  Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .

[9]  H. Aburatani,et al.  Hepatocellular carcinoma in Txnip-deficient mice , 2006, Oncogene.

[10]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Tagawa,et al.  High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. , 2008, The Journal of pathology.

[12]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[13]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[14]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[15]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[16]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.

[17]  Paolo Vineis,et al.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 , 2011, Nature Genetics.

[18]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[19]  J. Finke,et al.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. , 2003, Cancer research.

[20]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[21]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Ohh,et al.  Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2* , 2008, Journal of Biological Chemistry.

[23]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[24]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Mancarelli,et al.  The tumor suppressor gene KCTD11REN is regulated by Sp1 and methylation and its expression is reduced in tumors , 2010, Molecular Cancer.

[26]  D. Haber,et al.  salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines , 2002, Cell.

[27]  N. Bander,et al.  Establishment and characterization of human renal cancer and normal kidney cell lines. , 1990, Cancer research.

[28]  A. Abdollahi.  LOT1 (ZAC1/PLAGL1) and its family members: Mechanisms and functions , 2007, Journal of cellular physiology.

[29]  P. Heikkilä,et al.  Frequent loss of heterozygosity at 6q in pheochromocytoma. , 2006, Human pathology.

[30]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.

[31]  E. Rankin,et al.  Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice , 2008, Oncogene.

[32]  B. Rini.  New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance , 2010, Clinical Cancer Research.

[33]  C. Larsson,et al.  Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. , 2004, International journal of oncology.

[34]  R. Lazarus,et al.  Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations , 2007, Human Genetics.

[35]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[36]  A. Belldegrun,et al.  Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Delahunt,et al.  Chromosome 14q LOH in localized clear cell renal cell carcinoma , 2002, The Journal of pathology.

[38]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[39]  H. Grossman,et al.  Human renal carcinoma: Characterization of five new cell lines , 1985, Journal of surgical oncology.

[40]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo , 2006 .

[41]  Brian Keith,et al.  Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. , 2005, Cancer research.

[42]  W. Linehan,et al.  Molecular and cellular characterization of human renal cell carcinoma cell lines. , 1992, Cancer research.

[43]  K. Pacak,et al.  Downregulation of metastasis suppressor genes in malignant pheochromocytoma , 2005, International journal of cancer.

[44]  Yoji Andrew Minamishima,et al.  Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations , 2007, Molecular and Cellular Biology.

[45]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[46]  M. Simon,et al.  Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. , 2005, Cancer research.

[47]  William C Hahn,et al.  Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. , 2009, Cancer cell.

[48]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[49]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[50]  A. Harris,et al.  Effects of HIF-1α and HIF2α on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts , 2010, Journal of oncology.

[51]  Jan Lubinski,et al.  Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. , 2009, Anticancer research.

[52]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. , 2006, The EMBO journal.

[53]  L. Pylkkänen,et al.  Loss of Heterozygosity at 6q Is Frequent and Concurrent with 3p Loss in Sporadic and Familial Capillary Hemangioblastomas , 2004, Journal of neuropathology and experimental neurology.

[54]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .

[55]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[56]  J. Brugarolas,et al.  Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. , 2004, Cancer cell.

[57]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[58]  S. Bartz,et al.  The Hypoxia-Inducible Factor 2α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo , 2007, Molecular and Cellular Biology.